Tag:
Lupin
Latest Headlines
Latest Headlines
Bayer to face new Yaz rivals as patent goes up in flames
After taking a $500 million charge against 2012 earnings for Yaz and Yasmin-related litigation, Bayer has lost its patent fight with three generics makers intent on selling their own copycats.
Union sues Warner Chilcott, Watson and Lupin over alleged pay-for-delay deal
A union fund is suing Warner Chilcott, Watson Laboratories and Lupin, claiming that their Loestrin 24 Fe patent settlements amounted to unfair market-sharing deals that cost payers money. Warner's key patent on the formula was weak, the fund claims, and the generics makers only backed away because Warner paid them to.
Lupin eyes buyouts up to $500M in U.S. growth push
Lupin executives keep talking up their plans for U.S. expansion. Buying brands, buying companies, pumping up its own launches of generic drugs--the Indian drugmaker says it's going to pull out all the stops to build up its presence stateside.
India's Lupin shops for U.S. brands to bolster margins
Lupin is joining the list of genericsmakers looking toward branded drugs for growth. The Indian company is scouting for U.S. brands to buy, President Nilesh Gupta tells Bloomberg , particularly in the dermatology field.
No more working Saturdays at exports-minded Cipla
Why isn't Cipla as big as Ranbaxy Laboratories ? That's the central question of an Economic Times story profiling Chairman Yusuf Hamied and his company's recent changes. After years of promoting from
Lupin expands Japanese reach with I'Rom buy
India's Lupin has made a second foray into Japan , striking a deal to buy the Tokyo-based injectables maker I'Rom Pharmaceutical. The buyout follows Lupin's acquisition of Kyowa Pharmaceuticals, which
Takeda eyes Indian M&A, but Cipla, Lupin deny talks
Takeda Pharmaceutical is shopping in India, but whether it's buying is another story. Sources tell the Economic Times the Japanese drugmaker has been kicking tires over at Cipla and Lupin, both major
Medicis inks $58M dermatology pact with India's Lupin
The media blitz focused on Medicis CEO Jonah Shacknai in the wake of the bizarre death of his girlfriend hasn't prevented the company from completing new development pacts. While a U.S. subsidiary of
Lupin said to weigh sale of Indian pharma unit
Lupin's Indian drugs business may be on the block. Sources tell Bloomberg the company's founding shareholders, who together own 47% of the India-based company, are shopping the domestic drug
Lupin sets sights on birth control market
India's Lupin is eyeing a $200 million chunk of the U.S. contraceptive market. The company has asked FDA to approve 11 of its copycat oral contraceptives, and plans to file another 10 apps within
